ArticleBMC geriatrics2026
Sarcopenic obesity definitions and their association with cardiovascular disease and mortality.
Article in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interrelationship Between Sarcopenia, Frailty and Cardiovascular Disease-The Crucial Role of Obesity in Hypothesis Generation-A Narrative Review.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSarcopenic obesity (SO) is a prevalent geriatric syndrome with significant implications for cardiovascular health and survival. However, the absence of a standardised diagnostic consensus hinders risk stratification and targeted management in older adults. We evaluated SO prevalence using the ESPEN-EASO, FNIH, and EWGSOP2 criteria and assessed associations with cardiovascular disease (CVD) and all-cause mortality.
methodsWe analysed data from 121,111 UK Biobank participants aged ≥ 60 years. SO was operationally defined by ESPEN-EASO, FNIH, and EWGSOP2 criteria. We compared the prevalence and agreement among the three definitions. Cox-proportional hazard models were used to investigate the association between the combined categories of sarcopenia and obesity and the incidence of CVD and all-cause mortality.
resultsSO prevalence varied significantly: 2.28% (ESPEN-EASO), 0.28% (FNIH), and 0.01% (EWGSOP2), with poor inter-criteria agreement (kappa < 0.20). Among men, ESPEN-EASO-defined SO showed the strongest associations with incident CVD and all-cause mortality (HR 1.61, 95% CI 1.43–1.81; and HR 1.66, 95% CI 1.45–1.91, respectively). Among women, ESPEN-EASO-defined SO showed the strongest association with all-cause mortality (HR 1.59, 95% CI 1.37–1.83), whereas FNIH-defined SO showed the highest point estimate for incident CVD (HR 1.99, 95% CI 1.40–2.82). The EWGSOP2 criteria identified too few SO cases for robust prognostic assessment.
conclusionSO prevalence and prognostic performance differed substantially across consensus definitions. ESPEN-EASO identified more SO cases and showed more consistent associations with incident CVD and all-cause mortality in older adults. Regardless of definition, SO was associated with increased risks of incident CVD and all-cause mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.